{
    "doi": "https://doi.org/10.1182/blood.V120.21.666.666",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=2247",
    "start_url_page_num": 2247,
    "is_scraped": "1",
    "article_title": "Dasatinib (Sprycel\u00ae) and Low Intensity Chemotherapy for First-Line Treatment in Patients with De Novo Philadelphia Positive ALL Aged 55 and Over: Final Results of the EWALL-Ph-01 Study ",
    "article_date": "November 16, 2012",
    "session_type": "612. Acute Lymphoblastic Leukemia - Pathophysiology &amp; Clinical Studies: Treatment of High-risk Subsets and Complications",
    "topics": [
        "chemotherapy regimen",
        "dasatinib",
        "bcr-abl tyrosine kinase",
        "brachial plexus neuritis",
        "dexamethasone",
        "kinase inhibitors",
        "protein-tyrosine kinase inhibitor",
        "src-family kinases",
        "vincristine"
    ],
    "author_names": [
        "Philippe Rousselot, MD, PhD",
        "Marie Magdeleine Coude\u0301",
        "Franc\u0327oise Huguet",
        "Marina Lafage",
        "Thibaut Leguay",
        "Celia Salanoubat, MD",
        "Francis Witz, MD",
        "Magda Alexis, MD",
        "Maud Janvier, MD",
        "Mathilde Hunault, MD, PhD",
        "Philippe Agape",
        "Christian Berthou, MD",
        "Eric Jourdan, MD",
        "Jose\u0301 Fernandes, MD",
        "Laurent Sutton",
        "Anne Banos",
        "Oumedaly Reman, MD",
        "Bruno Lioure, MD",
        "Jean-Michel Cayuela, PhD",
        "Sandrine Hayette",
        "Nicola Gokbuget, MD",
        "Dieter Hoelzer, MD",
        "Andre Delannoy, MD",
        "Carlo Gambacorti-Passerini, MD",
        "Renato Bassan, MD",
        "Josep-Maria Ribera, MD, PhD",
        "Sebastian Giebel, MD",
        "Herve Dombret",
        "Oliver G. Ottmann, MD"
    ],
    "author_affiliations": [
        [
            "Service d'He\u0301matologie et Oncologie, Hopital de Versailles, Universite\u0301 Versailles Saint Quentin en Yvelines, Le Chesnay, France, "
        ],
        [
            "Molecular biology, Ho\u0302pital Saint-Louis AP-HP, "
        ],
        [
            "Hematology, Ho\u0302pital Purpan, Universite\u0301 Toulouse, Toulouse, France, "
        ],
        [
            "Cytogenetics, CHU Timone, Marseille, France, "
        ],
        [
            "Hematology, CHU Bordeaux, Ho\u0302pital Haut-leveque, Pessac, France, "
        ],
        [
            "Ho\u0302pital de Corbeil, Corbeil, France, "
        ],
        [
            "Hematology, CHU de Nancy, Nancy, France, "
        ],
        [
            "Haematology, CH Orleans, Orleans, France, "
        ],
        [
            "Institut Curie - Ho\u0302pital Rene Huguenin, Saint-Cloud, France, "
        ],
        [
            "Service d'he\u0301matologie, CHU, Angers, France, "
        ],
        [
            "Haematology, Hopital Felix Guyon, Saint Denis, Gabon, "
        ],
        [
            "Hematology, Brest University Hospital, Brest, France, "
        ],
        [
            "CHU Nimes, Universite\u0301 Nimes, Nimes, France, "
        ],
        [
            "CH de Valenciennes, Valenciennes, "
        ],
        [
            "CH Argenteuil, Argenteuil, France, "
        ],
        [
            "Centre Hospitalier de la Co\u0302te Basque, Bayonne, France, "
        ],
        [
            "CHU Caen, Universite\u0301 Caen, Caen, France, "
        ],
        [
            "CHU Hautepierre, Universite\u0301 Strasbourg, Strasbourg, France, "
        ],
        [
            "Laboratoire Central d'Hematologie, Hopital Saint-Louis, Paris, France, "
        ],
        [
            "Molecular Biology and Cytogenetics, Centre Hospitalier Lyon Sud, Pierre Benite, France, "
        ],
        [
            "Medical Department II, Hematology/Oncology, Goethe University Hospital, Frankfurt, Germany, "
        ],
        [
            "Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital, Frankfurt, Germany, "
        ],
        [
            "Cliniques universitaires Saint-Luc, Brussels, Belgium, "
        ],
        [
            "Dept. of Hematology, Universita\u0300 Milano Bicocca and S. Gerardo Hospital, Monza, Italy, "
        ],
        [
            "Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy, "
        ],
        [
            "IJC-ICO Badalona, Hospital Germans Trias i Pujol, Universitat Auto\u0300noma de Barcelona, Badalona, Badalona, Spain, "
        ],
        [
            "Department of Bone Marrow Transplantation, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland, "
        ],
        [
            "He\u0301matologie Adultes, Ho\u0302pital Saint-Louis, AP-HP, University Paris 7, EA 3518, Paris, France, "
        ],
        [
            "Dept. of Medicine, Hematology/Oncology, Goethe University, Frankfurt, Germany"
        ]
    ],
    "first_author_latitude": "48.83119659999999",
    "first_author_longitude": "2.1260800999999994",
    "abstract_text": "Abstract 666 Background. Dasatinib (Sprycel\u00ae, Bristol-Myers Squibb) is a potent multi-targeted kinase inhibitor (TKI) of BCR-ABL and SRC family kinases. The EWALL group for adult ALL decided to run a study at the European level evaluating the combination of dasatinib and chemotherapy for Philadelphia positive (Ph+) ALL patients (pts) aged 55 and over. Aim. To analyse efficacy of Dasatinib combined to low intensity chemotherapy and to test factors associated with outcome. (EudraCT 2006\u2013005694-21). Methods. After prephase, dasatinib was administered at 140 mg QD (100 mg over 70y) during the induction period in combination with weekly vincristine (VCR) 1 mg IV and dexamethasone (DEX) 40 mg for 2 days (20 mg over 70y) for 4 weeks. Consolidation View large Download slide View large Download slide  Disclosures: Rousselot: BMS, Novartis: Research Funding. Gambacorti-Passerini: BMS, Novartis: Research Funding."
}